Multiple Sclerosis: Symptoms, Diagnosis and Living With MS in Hyderabad

Multiple sclerosis (MS) is a chronic autoimmune condition in which the immune system attacks the myelin sheath — the protective coating around nerve fibres in the brain and spinal cord. The resulting inflammation and demyelination disrupt nerve conduction, producing the wide range of neurological symptoms characteristic of MS. MS primarily affects young adults — most commonly diagnosed between ages 20 and 40 — making it one of the most impactful neurological conditions in terms of life-years affected.

Symptoms of MS

Because MS lesions can occur anywhere in the CNS, symptoms are diverse and unpredictable. Common presentations include:

• Optic neuritis: Pain behind one eye, followed by vision loss — often the first symptom of MS. Typically recovers over weeks
• Transverse myelitis: Partial spinal cord inflammation causing leg weakness, urinary dysfunction, and a "band" sensation around the chest
• Brainstem symptoms: Double vision, vertigo, facial numbness
• Limb weakness and coordination: Unsteady gait, clumsiness, balance problems
• Fatigue: The most common and often most disabling symptom — an overwhelming exhaustion disproportionate to activity
• Cognitive symptoms: Slowed processing speed, memory difficulty, word-finding problems
• Uhthoff's phenomenon: Temporary worsening of symptoms with heat (hot shower, fever, exercise) — characteristic of MS

Diagnosis

MS diagnosis requires demonstration of lesions disseminated in space and time — multiple lesions in different CNS locations, occurring at different timepoints. The McDonald criteria are used: MRI brain and spinal cord showing characteristic white matter plaques; CSF analysis showing oligoclonal bands (immunoglobulins present in the CSF but not the blood); visual evoked potentials showing delayed conduction if optic neuritis has occurred. MRI is the cornerstone — modern MRI shows lesions invisible to clinical examination.

Types and Prognosis

Relapsing-remitting MS (RRMS, 85% of cases): Episodes of neurological dysfunction (relapses) followed by full or partial recovery. Between relapses, disability may be minimal. With modern disease-modifying therapy, most patients with RRMS have minimal disability accumulation over decades.

Disease-Modifying Therapies

The past two decades have produced remarkable advances in MS treatment. High-efficacy therapies (natalizumab, ocrelizumab, alemtuzumab, cladribine) reduce relapse rate by 70–95% and significantly prevent disability accumulation. Early initiation of high-efficacy therapy — rather than starting with low-efficacy medication and escalating — produces better long-term outcomes in most patients.

For MS diagnosis, MRI evaluation, and specialist management: Sri Anand CNC, Chanda Nagar, Hyderabad. Call +91 90633 66983.